Valeant Pharmaceuticals International IncVRX:TOR

170.47
5.01 / 3.03%
81.29k
43.29%
0.4893
Latest price in CADToday's changeShares traded1 year changeBeta
Data delayed at least 15 minutes, as of Dec 22 2014 15:20 GMT.

Summary

Valeant Pharmaceuticals International Inc (VRX:TOR) set a new 52-week high during today's trading session when it reached 174.08. Over this period, the share price is up 42.47%.

52-week range
Today
116.01
Aug 11 2014
174.08
Dec 22 2014
Markit short selling activity
Low
Medium
High
Open169.50
Day high174.08
Day low169.50
Bid170.44
Offer170.51
Previous close165.46
Average volume683.35k
Shares outstanding335.67m
Free float327.97m
P/E (TTM)96.52
Market cap55.54bn CAD
EPS (TTM)1.71 CAD
Data delayed at least 15 minutes, as of Dec 22 2014 15:20 GMT.

Comparative analysis

Past 90 days
1 week1 month6 months1 year5 years
Valeant Pharmaceuticals International Inc+5.78%+4.34%+29.24%+43.29%+1,049.49%
TSX-Toronto Stock Exchange 300 Compo+5.40%-4.41%-4.39%+7.80%+24.23%
CA/HEALTH CARE+2.55%+1.82%+19.96%+25.22%--
CA/PHARMACEUTICALS+2.60%+1.26%+20.28%+28.10%--
Data delayed at least 15 minutes, as of Dec 22 2014 15:20 GMT.
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.

Markit Short Selling Activity © Markit. All rights reserved.
Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.